WO2023157024A1 - Vaginal pharmaceutical composition comprising miconazole and luliconazole or salts thereof - Google Patents
Vaginal pharmaceutical composition comprising miconazole and luliconazole or salts thereof Download PDFInfo
- Publication number
- WO2023157024A1 WO2023157024A1 PCT/IN2023/050160 IN2023050160W WO2023157024A1 WO 2023157024 A1 WO2023157024 A1 WO 2023157024A1 IN 2023050160 W IN2023050160 W IN 2023050160W WO 2023157024 A1 WO2023157024 A1 WO 2023157024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salts
- vaginal
- pharmaceutical composition
- miconazole
- luliconazole
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 104
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 title claims abstract description 72
- 229960000570 luliconazole Drugs 0.000 title claims abstract description 71
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229960002509 miconazole Drugs 0.000 title claims abstract description 67
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 57
- 206010046914 Vaginal infection Diseases 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 6
- -1 douche Substances 0.000 claims description 31
- 206010017533 Fungal infection Diseases 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- 239000003995 emulsifying agent Substances 0.000 claims description 21
- 239000003755 preservative agent Substances 0.000 claims description 21
- 230000002335 preservative effect Effects 0.000 claims description 21
- 239000007957 coemulsifier Substances 0.000 claims description 16
- 239000000314 lubricant Substances 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 239000006071 cream Substances 0.000 claims description 13
- 239000003981 vehicle Substances 0.000 claims description 13
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 12
- 239000012071 phase Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 201000008100 Vaginitis Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000004945 emulsification Methods 0.000 claims description 7
- 239000008213 purified water Substances 0.000 claims description 7
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 6
- 206010044620 Trichomoniasis Diseases 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 239000002304 perfume Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000003381 solubilizing effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims description 3
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 3
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 3
- 241000606161 Chlamydia Species 0.000 claims description 3
- 206010018612 Gonorrhoea Diseases 0.000 claims description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 claims description 3
- 230000003113 alkalizing effect Effects 0.000 claims description 3
- 239000002518 antifoaming agent Substances 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000000227 bioadhesive Substances 0.000 claims description 3
- 239000006172 buffering agent Substances 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000003349 gelling agent Substances 0.000 claims description 3
- 208000001786 gonorrhea Diseases 0.000 claims description 3
- 239000003906 humectant Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 239000003961 penetration enhancing agent Substances 0.000 claims description 3
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 2
- 229940059082 douche Drugs 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 229940116641 vaginal film Drugs 0.000 claims description 2
- 229940044953 vaginal ring Drugs 0.000 claims description 2
- 239000006213 vaginal ring Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 16
- 230000002265 prevention Effects 0.000 abstract description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 208000031888 Mycoses Diseases 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 230000000843 anti-fungal effect Effects 0.000 description 9
- 229940121375 antifungal agent Drugs 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- 229960005040 miconazole nitrate Drugs 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000003429 antifungal agent Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 235000013772 propylene glycol Nutrition 0.000 description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000004166 Lanolin Substances 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000019388 lanolin Nutrition 0.000 description 6
- 229940039717 lanolin Drugs 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 6
- 239000005711 Benzoic acid Substances 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 4
- 206010007134 Candida infections Diseases 0.000 description 4
- 241001363490 Monilia Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 201000003984 candidiasis Diseases 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 229960004022 clotrimazole Drugs 0.000 description 4
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229920001206 natural gum Polymers 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 4
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- 229940044959 vaginal cream Drugs 0.000 description 4
- 239000000522 vaginal cream Substances 0.000 description 4
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 3
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 3
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 3
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 3
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000019489 Almond oil Nutrition 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 241000222178 Candida tropicalis Species 0.000 description 3
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 3
- 241001480036 Epidermophyton floccosum Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 241000223229 Trichophyton rubrum Species 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000008168 almond oil Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960003913 econazole Drugs 0.000 description 3
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 3
- 229940093471 ethyl oleate Drugs 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 229940074928 isopropyl myristate Drugs 0.000 description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
- 229940075495 isopropyl palmitate Drugs 0.000 description 3
- 229960004130 itraconazole Drugs 0.000 description 3
- 229960004125 ketoconazole Drugs 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229940058690 lanosterol Drugs 0.000 description 3
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940043348 myristyl alcohol Drugs 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229940100462 pegoxol 7 stearate Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 3
- 229960000580 terconazole Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 2
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 244000197813 Camelina sativa Species 0.000 description 2
- 241000222173 Candida parapsilosis Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000555688 Malassezia furfur Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 108010021062 Micafungin Proteins 0.000 description 2
- 241000893980 Microsporum canis Species 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 241000235645 Pichia kudriavzevii Species 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical compound CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 2
- 229940071161 dodecylbenzenesulfonate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 230000008686 ergosterol biosynthesis Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- MMKRHZKQPFCLLS-UHFFFAOYSA-N ethyl myristate Chemical compound CCCCCCCCCCCCCC(=O)OCC MMKRHZKQPFCLLS-UHFFFAOYSA-N 0.000 description 2
- MVLVMROFTAUDAG-UHFFFAOYSA-N ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC MVLVMROFTAUDAG-UHFFFAOYSA-N 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960004413 flucytosine Drugs 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002159 micafungin Drugs 0.000 description 2
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 229960003255 natamycin Drugs 0.000 description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229960003483 oxiconazole Drugs 0.000 description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229960004838 phosphoric acid Drugs 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229940068984 polyvinyl alcohol Drugs 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229960001589 posaconazole Drugs 0.000 description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 229940093625 propylene glycol monostearate Drugs 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229950005137 saperconazole Drugs 0.000 description 2
- 229960005429 sertaconazole Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960002607 sulconazole Drugs 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- 229960004214 tioconazole Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- MUZIZEZCKKMZRT-UHFFFAOYSA-N 1,2-dithiolane Chemical group C1CSSC1 MUZIZEZCKKMZRT-UHFFFAOYSA-N 0.000 description 1
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- QSWSKDXFOIOXKW-UHFFFAOYSA-N 1h-imidazole;nitric acid Chemical compound O[N+]([O-])=O.C1=CNC=N1 QSWSKDXFOIOXKW-UHFFFAOYSA-N 0.000 description 1
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- WDQOEAOLRIMQDA-UHFFFAOYSA-N 3-methylbutyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCC(C)C WDQOEAOLRIMQDA-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108010064760 Anidulafungin Proteins 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003055 Application site reaction Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- GHJWNRRCRIGGIO-UHFFFAOYSA-N Fosfluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(OP(O)(=O)O)CN1C=NC=N1 GHJWNRRCRIGGIO-UHFFFAOYSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 1
- 240000007597 Hymenaea verrucosa Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 241001291477 Malassezia restricta Species 0.000 description 1
- 241001291475 Malassezia slooffiae Species 0.000 description 1
- 241001291478 Malassezia sympodialis Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 241001480037 Microsporum Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 244000250129 Trigonella foenum graecum Species 0.000 description 1
- 235000001484 Trigonella foenum graecum Nutrition 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 229960003348 anidulafungin Drugs 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 229960002120 butoconazole nitrate Drugs 0.000 description 1
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940073642 ceteareth-30 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940056318 ceteth-20 Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960001489 deferasirox Drugs 0.000 description 1
- FMSOAWSKCWYLBB-VBGLAJCLSA-N deferasirox Chemical compound C1=CC(C(=O)O)=CC=C1N(N\C(N\1)=C\2C(C=CC=C/2)=O)C/1=C\1C(=O)C=CC=C/1 FMSOAWSKCWYLBB-VBGLAJCLSA-N 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 229960003937 efinaconazole Drugs 0.000 description 1
- NFEZZTICAUWDHU-RDTXWAMCSA-N efinaconazole Chemical compound N1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)CCC(=C)CC1 NFEZZTICAUWDHU-RDTXWAMCSA-N 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229950008518 fosfluconazole Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960000587 glutaral Drugs 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960001906 haloprogin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229940037626 isobutyl stearate Drugs 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Natural products CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229940073577 lithium chloride Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 229940074596 luliconazole topical cream Drugs 0.000 description 1
- 229940074594 luzu Drugs 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- CPXCDEMFNPKOEF-UHFFFAOYSA-N methyl 3-methylbenzoate Chemical compound COC(=O)C1=CC=CC(C)=C1 CPXCDEMFNPKOEF-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 229940114937 microcrystalline wax Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- WWJFFVUVFNBJTN-UHFFFAOYSA-N neopolyoxin C Natural products C=1C=C(O)C=NC=1C(O)C(C)C(N)C(=O)NC(C(O)=O)C(C(C1O)O)OC1N1C=CC(=O)NC1=O WWJFFVUVFNBJTN-UHFFFAOYSA-N 0.000 description 1
- WWJFFVUVFNBJTN-VHDFTHOZSA-N nikkomycin Z Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)[C@H](NC(=O)[C@@H](N)[C@H](C)[C@H](O)C=2N=CC(O)=CC=2)C(O)=O)C=CC(=O)NC1=O WWJFFVUVFNBJTN-VHDFTHOZSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- MOQRZWSWPNIGMP-UHFFFAOYSA-N pentyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCC MOQRZWSWPNIGMP-UHFFFAOYSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 229940100528 polyoxyl 8 stearate Drugs 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229940093932 potassium hydroxide Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- DPBVJRXPSXTHOL-UHFFFAOYSA-N propyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCC DPBVJRXPSXTHOL-UHFFFAOYSA-N 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 1
- 229950004154 ravuconazole Drugs 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 229950003429 sorbitan palmitate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ACTRVOBWPAIOHC-UHFFFAOYSA-N succimer Chemical compound OC(=O)C(S)C(S)C(O)=O ACTRVOBWPAIOHC-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 235000001019 trigonella foenum-graecum Nutrition 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229940075466 undecylenate Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Definitions
- the present invention relates to a vaginal pharmaceutical composition
- a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts for the treatment of vaginal infections.
- the present invention relates to a vaginal pharmaceutical composition for treating vaginal infections and process of preparation thereof.
- the present invention relates to a vaginal pharmaceutical composition
- a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts and at least one pharmaceutically acceptable excipient and its preparation process and method of using the same for the treatment of vaginal infections.
- Vaginal yeast infection is a common fungal infection of the genitals. Approximately 20% of women get an infection yearly. About 75% of women have at least one infection in their lifetime. Vulvovaginal candidiasis is a relatively common form of yeast infection. Yeast infections also termed Candidiasis, Moniliasis, or Monilia vaginitis are among the most frequently occurring of vaginal infections. These vaginal infections are caused by fungus-like yeasts of the genus Candida (formerly Monilia), and specifically the species including C. albicans, C. tropicalis, C. psuedotropicalis, C. glabrata, C. parapsilosis, C. krusei, C. stellatoidea, as well as Bacteroides fragilis and Gardnerella vaginalis. Generally, 90% yeast infections caused by Candida albicans.
- Candida fungal microorganisms normally grow and thrive at low concentrations in the mouth, gastrointestinal tract, and vagina, coexisting with the normal biological flora in these regions, without adverse effect on health or physiological function. Lactobacillus bacteria keep its growth in check. But if there’s an imbalance in system, these bacteria won’t work effectively. This leads to an overgrowth of yeast, which causes the symptoms of vaginal yeast infections such as vaginal itching, swelling around the vagina, burning during urination or sex, pain during sex, soreness, redness, rash and vaginal discharge.
- vaginal infections are yeast infections, bacterial vaginosis, trichomoniasis, a sexually transmitted infection (STIs), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis and atrophic vaginitis.
- Candida infections typically involves the application of an anti-yeast medication to the vagina, with intravaginal administration of medicine being repeated at selected intervals over a period of days or weeks.
- Miconazole nitrate is an imidazole synthetic antifungal agent. It selectively affects the integrity of fungal cell membranes. Chemically Miconazole nitrate is l-[2, 4-dichloro-B- ⁇ (2,4-dichlorobenzyl)oxy ⁇ phenethyl] imidazole mononitrate and its molecular weight is of 479.15. Its empirical formula is CixHi-iCi-ikChHNCh. Miconazole nitrate is represented by compound of structural formula I. ,01
- Luliconazole is an imidazole antifungal drug. Chemically Luliconazole is (2E)-2-[(4R)-4-
- R enantiomer and contains one chiral center.
- the double bond adjacent to the dithiolane group is in the E configuration. Its molecular weight is of 354.28. Its empirical formula is C14H9Q2N3S2. Luliconazole is represented by compound of structural formula II.
- Luliconazole is a light yellow to yellow solid. It is low soluble in water, soluble in Acetonitrile, Dimethyl sulfoxide and slightly soluble in Chloroform and Methanol.
- Luliconazole topical cream (1%) was approved in USA on Nov 14, 2013 under the trade name “Luzu” and is indicated for the treatment of interdigital tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophytonfloccosum, in patients 18 years of age and older.
- U.S. Patent No. 10086008 discloses topical paste comprising one or more antifungal agents, excipient inert powder and pharmaceutically acceptable topical carrier.
- This patent application generically discloses antifungal agent such as clotrimazole, ketoconazole, miconazole, oxiconazole, econazole, luliconazole, terbinafine, nystatin, fluconazole, voriconazole, itraconazole, caspofungin, micafungin, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, sertaconazole, efinaconazole, enilaconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), pimaricin, griseofulvin, haloprogin,
- WO2011121604 discloses liquid vaginal spray dosage form comprising therapeutically effective amount of at least one antifungal agent along with lactic acid; wherein antifungal agent is selected from Miconazole, Ketoconazole, Clotrimazole, Econazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Griseofulvin, Fluconazole Fosfluconazole, Itraconazole, Posaconazole, Voriconazole, Amorolfme, Butenafme, Naftifme, Terbinafme, Terbinafme, Natamycin, Nystatin, Amphotericin B, Thiabendazole, Anidulafungin, Caspofungin, Micafungin, Flucytosine; however it does not teaches or discloses vaginal composition of Miconazole and Luliconazole
- vaginal fungal infection treatment includes Butoconazole Nitrate as vaginal cream 2%, Clotrimazole as Topical cream 1%, Miconazole as vaginal cream 4%, suppository of lOOmg and 200mg strength, Terconazole as cream in 0.4%, 0.8% strength and also as suppository of 80mg strength, Fluconazole as tablet in 50mg, lOOmg, 150mg, 200mg strengths.
- Luliconazole The most common adverse effect of product known in the prior art for Luliconazole is application site reactions and for Miconazole are allergic contact dermatitis, cellulitis, irritation, burning, maceration; therefore, these product does not provide patient compliance in the treatment of vaginal fungal infection.
- Vaginal infections are very common, because there are many factors that can interfere with the vaginal flora, which reduces vaginal resistance to infection, such as but not limited to bacterial and fungal infections. Therefore, it has important clinical significance for the prevention and treatment of reproductive tract infections if it inhibits harmful bacteria and fungi.
- vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole and Luliconazole with minimum adverse effects, with broad spectrum of antifungal activity, which is efficient and provides better patient compliance in the treatment of vaginal fungal infection.
- applicant of the present invention invented a novel vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts which is efficient, having broad spectrum of activity against vaginal infections with minimum adverse effect and better patient compliance.
- vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more of pharmaceutically acceptable excipient.
- It is an object of the present invention to provide a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
- vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more of pharmaceutically acceptable excipient.
- vaginal pharmaceutical composition for treating vaginal infections, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle.
- vaginal pharmaceutical composition comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0. 1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle.
- vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with broad spectrum of antifungal activity in the treatment of vaginal fungal infection.
- a further object of the invention is to provide a process for the preparation of a vaginal pharmaceutical composition, comprising Miconazole or its salts and Luliconazole or its salts, comprising:
- Aqueous phase dissolving preservative in purified water, mixing and heating at suitable temperature;
- Lipid phase Mixing co-emulsifier, emulsifier, lubricant and preservative and heating at suitable temperature;
- step (c) Cooling the lipid phase of step (b) at suitable temperature and mixing both active pharmaceutical ingredients (APIs) for 5-10 minutes;
- step (d) Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes;
- step (e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
- a main aspect, the present invention discloses a vaginal pharmaceutical composition
- a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
- the present invention relates to a vaginal pharmaceutical composition for treating vaginal infections, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0. 1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
- the present invention relates to a vaginal pharmaceutical composition, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0. 1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
- the present invention provides a process for the preparation of a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts, comprising:
- Aqueous phase dissolving preservative in purified water, mixing and heating at suitable temperature;
- step (c) Cooling the lipid phase of step (b) at suitable temperature and mixing both active pharmaceutical ingredients (APIs) for 5-10 minutes;
- Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes; and
- step (e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
- composition or “pharmaceutical composition” or “vaginal pharmaceutical composition” or “topical pharmaceutical composition” as used herein synonymously include dosage forms such as topical, cream, ointment or the like.
- infection or "vaginal infections” or “fungal infections” or “yeast infections” or “Vaginal yeast infections” or “vaginal fungal infection” as used herein synonymously.
- the present invention relates to vaginal pharmaceutical composition
- vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
- the present invention relates to vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
- the Miconazole and Luliconazole of the present inventions may be present in the form of free base or its pharmaceutically acceptable salt.
- Miconazole is used in broad sense to include not only “Miconazole” per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs thereof and also its various crystalline and amorphous forms.
- the salts of Miconazole may be selected from nitrate, maleate, hemifumarate, hemisuccinate and the like; preferably Miconazole nitrate salt is used.
- the concentration of Miconazole or its salts is at least 0.1%; preferably range from 0.1% to 10%; more preferably from 0.25% to 5% by total weight of composition.
- Liconazole is used in broad sense to include not only “Luliconazole” per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs thereof and also its various crystalline and amorphous forms.
- the salts of Luliconazole may be selected from formic acid, acetic acid, citric acid, tartaric acid, bitartaric acid, benzoic acid, lactic acid, malic acid, fumaric acid, succinic acid, gluconic acid, pamoic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid or the like.
- the concentration of Luliconazole or its salts is at least 0.01%; preferably ranges from 0.01 to 5%; more preferably from 0.1% to 4% by weight of the composition.
- vaginal infections as used in the present invention can be the groups of vaginal infections are yeast infections, bacterial vaginosis, trichomoniasis, a sexually transmitted infection (STIs), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis and atrophic vaginitis.
- yeast infections yeast infections
- bacterial vaginosis bacterial vaginosis
- trichomoniasis a sexually transmitted infection
- chlamydia or gonorrhea chlamydia or gonorrhea
- viral vaginitis herpes
- trichomoniasis non-infectious vaginitis and atrophic vaginitis.
- Miconazole and Luliconazole of present invention act as an antifungal which inhibit/prevent vaginal fungal infections.
- Miconazole acts by inhibiting the 14a-demethylation of lanosterol, which consequently leads to the inhibition of ergosterol synthesis in fungal cell membranes. Additionally, Miconazole has been shown to induce reactive oxygen species in fungal biofdms, demonstrating a MIC value of >256pM against Candida spp.
- Luliconazole acts by inhibiting the ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol.
- the vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts; wherein Miconazole or its salts and Luliconazole or its salts is providing potent antifungal activity, efficacy and patient compliance in the treatment of vaginal fungal infection.
- the vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention broaden the spectrum of activity, enhance the rate or extent of antifungal or antibacterial activity and reduce toxicities for the treatment of vaginal fungal infection.
- the present invention provides a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
- the present invention discloses a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
- the present invention discloses a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
- the vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
- the vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts may contain one or more pharmaceutically acceptable excipient selected from the group consisting of bases, emollients, lubricant, thickening agent or thickeners, surfactants, solubilizing or emulsifying agent or emulsifier, co-emulsifier, preservative, antioxidant, humectant, absorbent, permeation enhancer, opacifying agent, chelating agent, gelling agent, acidifying or alkalizing or buffering agent, perfumes or fragrances, antifoaming agent, adherent agent, bioadhesive polymer, vehicle and any other excipient known to the art for making pharmaceutical composition.
- bases emollients
- lubricant lubricant
- thickening agent or thickeners thickeners
- surfactants solubilizing or emulsifying agent or emulsifier
- co-emulsifier
- bases according to the present invention include but not limited to group comprising of carnauba wax, cetyl alcohol, cetyl ester wax, emulsifying wax, hydrous lanolin, lanolin, lanolin alcohols, vegetable oils and animal fat; coconut oil, bees wax, olive oil, spermaceti wax, sesame oil, almond oil, alcohols, acids and esters; oleic acid, oleyl alcohol, palmitic acid, lauryl alcohol, lauraic acid, myristyl alcohol, ethyl oleate, isopropyl myristicate, ethylene glycol, hydrogenated and sulphated oils; hydrogenated castor, cotton seed, hydrogenated sulphated castor oils, microcrystalline wax, liquid paraffin, petrolatum, polyethylene glycol, stearic acid, stearyl alcohol, white wax, yellow wax or combination thereof.
- emollients include but not limited to group comprising of waxes, fats, caprylic/capric triglyerides, castor oil, ceteareth-20, ceteareth-30, cetearyl alcohol, ceteth 20, cetostearyl alcohol, cetyl alcohol, cetyl stearyl alcohol, cocoa butter, di-isopropyladipate, glycerin, glyceryl monooleate, glyceryl monostearate, glyceryl stearate, isopropyl myristate, isopropyl palmitate, lanolin, lanolin alcohol, hydrogenated lanolin, liquid paraffins, linoleic acid, mineral oil, oleic acid, white petrolatum, polyethylene glycol, polyoxyethylene glycol fatty alcohol ethers, poly oxypropylene 15 -stearyl ether, propylene glycol stearate, squalane, steareth-2 or -
- thickening agent or thickeners include but not limited to group comprising of carbomer, hydrogenated castor oil, methyl cellulose, sodium carboxyl methyl cellulose, carrageenan, colloidal silicon dioxide, natural gum such as gelatin, tragacanth gum and guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxide, alginic acid, paraffin, cetostearyl alcohol, PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene sorbiton monoleate, and poloxamers, polyvinyl pyrrolidone, various alcohols such as polyvinyl alcohol, ethanol or isopropyl alcohol, fumed silica or combination thereof.
- solubilizing or emulsifying agent or emulsifier include but not limited to group comprising of apricot kernel oil PEG-6 ester, pegoxol-7 stearate, polysorbate 20, polysorbate 80, polysorbate 60, poloxamer, emulsifying wax, sorbitan monostearate, sorbitan monooleate, sodium lauryl sulfate, propylene glycol monostearate, natural gums like acacia and tragacanth, monovalent and bivalent soaps, lanolin, cholesterol or cholesterol esters, triethanolamine and its salts, dodecyl benzene sulfonate, diethylene glycol monoethyl ether, docusate sodium or mixture thereof, the amount of solubilizing or emulsifying agent or emulsifier present in the composition ranges from about 0.1-25%; preferably 1 to 22% by weight of composition.
- co-emulsifier examples include but not limited to group comprising of apricot kernel oil PEG-6 ester, propylene glycol stearate, cetyl hydroxyethyl cellulose, poloxamer 407, polyglyceryl-2 stearate or combination thereof, the amount of co-emulsifier present in the composition ranges from about 0.1-10%; preferably 0.05 to 8% by weight of composition.
- preservative include but not limited to group comprising of chorocresol, benzoic acid, butylated hydroxyanisole, phenyl mercuric nitrate, benzyl alcohol, benzoic acid and its salts, boric acid, methyl paraben, propyl paraben, trihydrate and anhydrous sodium acetate, chlorhexidine, formaldehyde, glutaraldehyde, imidazolidinyl urea, trichlosan, benzalkonium chloride, chloroxylenol or combination thereof, the amount of preservative present in the composition may ranges from about 0.001- 6%; preferably about 0.001-5%; more preferably about 0.005-4.5% by weight of composition.
- antioxidant include but not limited to group comprising of butylated hydroxylanisole, butylated hydroxyl toluene, propyl gallate, polyols like sorbitol, xylitol and maltitol, natural extracts like quillaia, or lactic acid or urea, lithium chloride, ascorbic acid, sodium metabisulfite, carotinoids, carotenes such as a- carotone, P-carotene and lycopene, chlorogenic acid, tocopherols, uric acid, zno, znso4 or combination thereof.
- permeation enhancer include but not limited to group comprising of propylene glycol, ethanol, isopropyl alcohol, oleic acid, polyethylene glycol, phospholipids, cyclodextrins, black pepper (piper nigrum), pyrrolidones, dimethyl sulphoxide (dmso), decylmethyl sulphoxide (dems), terpenes (cineole, eugenol, d- limonene, menthol, menthone), urea or combination thereof.
- opacifying agent examples include but not limited to group comprising of higher fatty alcohols such as cetyl, stearyl, cetostearyl alcohol, arachidyl and behenyl alcohols, solid esters such as cetyl palmitate, glyceryl laurate, various fatty acid derivatives such as propylene glycol and polyethylene glycol esters, inorganic materials such as, magnesium aluminum silicate, zinc oxide, titanium dioxide or other sunblocking agents or combination thereof.
- higher fatty alcohols such as cetyl, stearyl, cetostearyl alcohol, arachidyl and behenyl alcohols
- solid esters such as cetyl palmitate, glyceryl laurate
- various fatty acid derivatives such as propylene glycol and polyethylene glycol esters
- inorganic materials such as, magnesium aluminum silicate, zinc oxide, titanium dioxide or other sunblocking agents or combination thereof.
- chelating agent include but not limited to group comprising of ethylene diamine tetraacetate, dimercaprol, dimercaptosuccinic acid, penicillamine, deferoxamine, deferasirox, citric acid, maleic acid, phosphoric acid or combination thereof.
- acidifying or alkalizing or buffering agent include but not limited to group comprising of anhydrous and monohydrate citric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium sorbate, monobasic and dibasic sodium phosphate, trolamine or combination thereof.
- perfume or fragrances according to the present invention include but not limited to group comprising of lavender, lemon, gardenia, hypo allergenic perfume, menthol or combination thereof.
- adherent agent examples include but not limited to group comprising of natural gum (arabic, align, guar, tragacanth and xanthan gums, pectin and dextran) or combination thereof.
- natural gum arabic, align, guar, tragacanth and xanthan gums, pectin and dextran
- bioadhesive polymer include but not limited to group comprising of ethyl cellulose, polyvinylpyrrolidone, hydroxyl propyl methyl cellulose, hydroxyl propyl cellulose, hydroxyl ethyl cellulose, ethyl cellulose or combination thereof.
- vehicle include but not limited to group comprising of purified water, hexylene glycol, propylene glycol, oleyl alcohol, propylene carbonate, mineral oil, almond oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, myristyl alcohol, octyldodecanol, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, polyethylene glycol, diethylene glycol monoethyl, glycofurol, benzyl alcohol, labrasol, benzyl benzoate and ethyl oleate, diethylene glycol monoethyl ether, ethyl alcohol, cremophore ELP, solutol, transcutol, capmul, captex or mixture thereof.
- the vehicle is water.
- the vehicle according to present invention may be present in an amount to make up volume to quantity sufficient
- the present invention provides a vaginal pharmaceutical composition for treating vaginal infections, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
- the present invention provides a vaginal pharmaceutical composition, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
- the present invention provides a process of preparation of a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts, comprising:
- Aqueous phase dissolving preservative in purified water, mixing and heating at suitable temperature;
- step (d) Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes;
- step (e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
- vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salt and Luliconazole or salts, wherein said vaginal pharmaceutical composition can be applied at least once a day or as per instructions of healthcare provider.
- vaginal pharmaceutical composition according to present invention can be applied to affected part through hand or suitable applicator.
- the vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or salts comprises other pharmaceutically acceptable polymers mainly used for to maintain proper viscosity of formulation.
- the vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be manufactured by trituration method, levigation method, fusion method, chemical reaction method, emulsification method, cold method, dispersion method, moulding, compression, hand rolling and shaping, pour moulding, wet granulation, dry granulation or direct compression.
- the concentration of active ingredient Miconazole or its salts and Luliconazole or its salts and other excipients, manufacturing process has been optimized in way such that composition will have maximum therapeutic efficacy in the treatment of vaginal fungal infection with minimum or no side effects and which results in better patient compliance.
- the synergism of Miconazole or its salts and Luliconazole or its salts according to present invention broaden the spectrum of activity, enhance the rate or extent of antifungal or antibacterial activity, and reduce toxicities in the treatment of vaginal fungal infection.
- vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts is evaluated by determination of pH, primary skin irritation test, visual appearance, viscosity, spreadability, stability studies, rheological studies, thermal behavior, saponification value and acid value.
- vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be loaded for stability studies as per ICH guidelines.
- the vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be packaged in to the collapsible tubes, jars, pot, bottle or single dose packets.
- the container material or packaging material of the present invention does not affect the quality of the preparation or does not allow diffusion of any kind into or across the material of the container into the preparation.
- vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be labeled according to the requirement under Good Manufacturing Practice.
- Aqueous phase Benzoic Acid was dissolved in purified water, mixed and heated at 65- 75°C; 2.
- Lipid phase Apricot kernel oil PEG-6 Ester, Pegoxol-7 Stearate, Mineral oil, Butylated hydroxyanisole mixed and heated at 65-75°C;
- Step 2 phase was allowed to cool at 65 °C and both active pharmaceutical ingredients (APIs) Miconazole nitrate and Luliconazole were mixed for 5-10 minutes;
- APIs active pharmaceutical ingredients
- step 4 Emulsification was achieved by addition of step 3 to step 1, mixed for 10 minutes, and 5. Manufactured cream was mixed slowly and allowed to cool down at Room temperature.
- Example 2 Cream base approach with change in emulsifier and preservative: q.s.: Quantity sufficient Manufacturing process:
- Aqueous phase Benzoic Acid was dissolved in purified water, mixed and heated at 65- 75°C;
- Lipid phase Apricot kernel oil PEG-6 Ester, Pegoxol-7 Stearate, Mineral oil, mixed and heated at 65-75°C;
- Step 2 phase was allowed to cool at 65 °C and both active pharmaceutical ingredients (APIs) Miconazole nitrate and Luliconazole were mixed for 5-10 minutes;
- APIs active pharmaceutical ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A present invention relates to a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts, its process of preparation and its use for the treatment/prevention of vaginal infections.
Description
VAGINAL PHARMACEUTICAL COMPOSITION COMPRISING MICONAZOLE AND LULICONAZOLE OR SALTS THEREOF
FIELD OF THE INVENTION
The present invention relates to a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts for the treatment of vaginal infections.
Particularly, the present invention relates to a vaginal pharmaceutical composition for treating vaginal infections and process of preparation thereof.
More particularly, the present invention relates to a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts and at least one pharmaceutically acceptable excipient and its preparation process and method of using the same for the treatment of vaginal infections.
BACKGROUND OF THE INVENTION
Vaginal yeast infection is a common fungal infection of the genitals. Approximately 20% of women get an infection yearly. About 75% of women have at least one infection in their lifetime. Vulvovaginal candidiasis is a relatively common form of yeast infection. Yeast infections also termed Candidiasis, Moniliasis, or Monilia vaginitis are among the most frequently occurring of vaginal infections. These vaginal infections are caused by fungus-like yeasts of the genus Candida (formerly Monilia), and specifically the species including C. albicans, C. tropicalis, C. psuedotropicalis, C. glabrata, C. parapsilosis, C. krusei, C. stellatoidea, as well as Bacteroides fragilis and Gardnerella vaginalis. Generally, 90% yeast infections caused by Candida albicans.
These Candida fungal microorganisms normally grow and thrive at low concentrations in the mouth, gastrointestinal tract, and vagina, coexisting with the normal biological flora in these regions, without adverse effect on health or physiological function. Lactobacillus bacteria keep its growth in check. But if there’s an imbalance in system, these bacteria won’t work effectively. This leads to an overgrowth of yeast, which causes the symptoms of vaginal yeast infections such as vaginal itching, swelling around the vagina, burning during urination or sex, pain during sex, soreness, redness, rash and vaginal discharge.
The types of vaginal infections are yeast infections, bacterial vaginosis, trichomoniasis, a sexually transmitted infection (STIs), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis and atrophic vaginitis.
For intravaginal treatment various types of tablets, capsules, foams, pessaries, ointments and creams containing various conventional drugs in conventional delivery systems have been introduced for either short or long term therapy. More effective treatment of Candida infections typically involves the application of an anti-yeast medication to the vagina, with intravaginal administration of medicine being repeated at selected intervals over a period of days or weeks.
Miconazole nitrate is an imidazole synthetic antifungal agent. It selectively affects the integrity of fungal cell membranes. Chemically Miconazole nitrate is l-[2, 4-dichloro-B- {(2,4-dichlorobenzyl)oxy} phenethyl] imidazole mononitrate and its molecular weight is of 479.15. Its empirical formula is CixHi-iCi-ikChHNCh. Miconazole nitrate is represented by compound of structural formula I. ,01
Cl
Formula I
Miconazole nitrate is a white to almost white powder. It is soluble in water and organic solvents such as ethanol, DMSO and dimethyl formamide (DMF), propylene glycol or pyridine.
Miconazole nitrate vaginal cream 2% and 4% was approved in USA on Feb 15, 1991 and Mar 30, 1998 under the trade name “MONISTAT 7” and “MONISTAT 3” respectively and was indicated for the treatment of vaginal yeast infections and relieves external itching and irritation associated with it.
Luliconazole is an imidazole antifungal drug. Chemically Luliconazole is (2E)-2-[(4R)-4-
(2,4-dichlorophenyl)-l,3-dithiolan-2-ylidene]-2-imidazol-l-ylacetonitrile. Luliconazole is the
R enantiomer and contains one chiral center. The double bond adjacent to the dithiolane group is in the E configuration. Its molecular weight is of 354.28. Its empirical formula is C14H9Q2N3S2. Luliconazole is represented by compound of structural formula II.
Formula II
Luliconazole is a light yellow to yellow solid. It is low soluble in water, soluble in Acetonitrile, Dimethyl sulfoxide and slightly soluble in Chloroform and Methanol.
Luliconazole topical cream (1%) was approved in USA on Nov 14, 2013 under the trade name “Luzu” and is indicated for the treatment of interdigital tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophytonfloccosum, in patients 18 years of age and older.
U.S. Patent No. 10086008 discloses topical paste comprising one or more antifungal agents, excipient inert powder and pharmaceutically acceptable topical carrier. This patent application generically discloses antifungal agent such as clotrimazole, ketoconazole, miconazole, oxiconazole, econazole, luliconazole, terbinafine, nystatin, fluconazole, voriconazole, itraconazole, caspofungin, micafungin, naftifine, butenafine, amorolfine, ravuconazole, posaconazole, flucytosine, sertaconazole, efinaconazole, enilaconazole, saperconazole, sulconazole, terconazole, tioconazole, nikkomycin Z, anidulafungin (LY303366), pimaricin, griseofulvin, haloprogin, tolnaftate, undecylenate, or any combination thereof. Further this patent application specifically discloses terbinafine or terbinafine hydrochloride containing antifungal composition; however it does not teaches or discloses vaginal composition of Miconazole and Luliconazole.
U.S. Patent No. 5514698 discloses a long-lasting viscous antifungal vaginal cream composition comprising an imidazole antifungal drug from miconazole, econazole, terconazole, saperconazole, itraconazole, ketoconazole, and clotrimazole; however it does not teaches or discloses vaginal composition of Miconazole and Luliconazole.
PCT Publication No. WO2011121604 discloses liquid vaginal spray dosage form comprising therapeutically effective amount of at least one antifungal agent along with lactic acid; wherein antifungal agent is selected from Miconazole, Ketoconazole, Clotrimazole, Econazole, Bifonazole, Butoconazole, Fenticonazole, Isoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Griseofulvin, Fluconazole Fosfluconazole, Itraconazole, Posaconazole, Voriconazole, Amorolfme, Butenafme, Naftifme, Terbinafme, Terbinafme, Natamycin, Nystatin, Amphotericin B, Thiabendazole, Anidulafungin, Caspofungin, Micafungin, Flucytosine; however it does not teaches or discloses vaginal composition of Miconazole and Luliconazole.
Currently, commercially available marketed product in the vaginal fungal infection treatment includes Butoconazole Nitrate as vaginal cream 2%, Clotrimazole as Topical cream 1%, Miconazole as vaginal cream 4%, suppository of lOOmg and 200mg strength, Terconazole as cream in 0.4%, 0.8% strength and also as suppository of 80mg strength, Fluconazole as tablet in 50mg, lOOmg, 150mg, 200mg strengths.
The most common adverse effect of product known in the prior art for Luliconazole is application site reactions and for Miconazole are allergic contact dermatitis, cellulitis, irritation, burning, maceration; therefore, these product does not provide patient compliance in the treatment of vaginal fungal infection.
In the marketed products there is no combination of Miconazole and Luliconazole is available, hence there is unmet need to develop a vaginal pharmaceutical composition comprising combination of Miconazole or its salts and Luliconazole or its salts.
Vaginal infections are very common, because there are many factors that can interfere with the vaginal flora, which reduces vaginal resistance to infection, such as but not limited to bacterial and fungal infections. Therefore, it has important clinical significance for the
prevention and treatment of reproductive tract infections if it inhibits harmful bacteria and fungi.
Therefore, there is an unmet need in the art to develop a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole and Luliconazole with minimum adverse effects, with broad spectrum of antifungal activity, which is efficient and provides better patient compliance in the treatment of vaginal fungal infection.
Accordingly, applicant of the present invention invented a novel vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts which is efficient, having broad spectrum of activity against vaginal infections with minimum adverse effect and better patient compliance.
OBJECTS OF THE INVENTION
It is an object of the present invention to provide a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more of pharmaceutically acceptable excipient.
It is an object of the present invention to provide a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
It is an object of the present invention to provide a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more of pharmaceutically acceptable excipient.
It is an object of the present invention to provide a vaginal pharmaceutical composition for treating vaginal infections, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle.
It is an object of the present invention to provide a vaginal pharmaceutical composition, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0. 1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle.
It is further object of the present invention to provide a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with broad spectrum of antifungal activity in the treatment of vaginal fungal infection.
A further object of the invention is to provide a process for the preparation of a vaginal pharmaceutical composition, comprising Miconazole or its salts and Luliconazole or its salts, comprising:
(a) Aqueous phase: dissolving preservative in purified water, mixing and heating at suitable temperature;
(b) Lipid phase: Mixing co-emulsifier, emulsifier, lubricant and preservative and heating at suitable temperature;
(c) Cooling the lipid phase of step (b) at suitable temperature and mixing both active pharmaceutical ingredients (APIs) for 5-10 minutes;
(d) Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes; and
(e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
SUMMARY OF THE INVENTION
A main aspect, the present invention discloses a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
In one aspect, the present invention discloses a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
In another aspect, the present invention relates to a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
In another aspect, the present invention relates to a vaginal pharmaceutical composition for treating vaginal infections, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0. 1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
In another aspect, the present invention relates to a vaginal pharmaceutical composition, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0. 1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
In another aspect, the present invention provides a process for the preparation of a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts, comprising:
(a) Aqueous phase: dissolving preservative in purified water, mixing and heating at suitable temperature;
(b) Lipid phase: Mixing co-emulsifier, emulsifier, lubricant, and preservative and heating at suitable temperature;
(c) Cooling the lipid phase of step (b) at suitable temperature and mixing both active pharmaceutical ingredients (APIs) for 5-10 minutes;
(d) Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes; and
(e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
In another aspect of the present invention is to provide a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
DETAIL DESCRIPTION OF THE INVENTION
The term "composition" or "pharmaceutical composition" or "vaginal pharmaceutical composition" or “topical pharmaceutical composition” as used herein synonymously include dosage forms such as topical, cream, ointment or the like.
The term "infection" or "vaginal infections" or "fungal infections" or “yeast infections” or “Vaginal yeast infections” or “vaginal fungal infection” as used herein synonymously.
In the following specification and the claims, reference will be made to a number of terms, which shall be defined to have the following meanings. The singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise.
The present invention relates to vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
The present invention relates to vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
The Miconazole and Luliconazole of the present inventions may be present in the form of free base or its pharmaceutically acceptable salt.
The term “Miconazole” is used in broad sense to include not only “Miconazole” per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs thereof and also its various crystalline and amorphous forms.
The salts of Miconazole may be selected from nitrate, maleate, hemifumarate, hemisuccinate and the like; preferably Miconazole nitrate salt is used.
The concentration of Miconazole or its salts is at least 0.1%; preferably range from 0.1% to 10%; more preferably from 0.25% to 5% by total weight of composition.
The term “Luliconazole” is used in broad sense to include not only “Luliconazole” per se but also its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, derivatives, isomers, polymorphs, prodrugs thereof and also its various crystalline and amorphous forms.
The salts of Luliconazole may be selected from formic acid, acetic acid, citric acid, tartaric acid, bitartaric acid, benzoic acid, lactic acid, malic acid, fumaric acid, succinic acid, gluconic acid, pamoic acid, methanesulfonic acid, benzenesulfonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid or the like.
The concentration of Luliconazole or its salts is at least 0.01%; preferably ranges from 0.01 to 5%; more preferably from 0.1% to 4% by weight of the composition.
The term “fungal infection” as used in the present invention can be selected from the group of vaginal candidiasis (Candida) or moniliasis, or monilia vaginitis, caused by fungus-like yeasts of the genus Candida (formerly Monilia), and fungal infections caused specifically by the species including C. albicans, C. tropicalis, C. psuedotropicalis, C. glabrata, C. parapsilosis, C. krusei and C. stellatoidea.
The vaginal infections as used in the present invention can be the groups of vaginal infections are yeast infections, bacterial vaginosis, trichomoniasis, a sexually transmitted infection (STIs), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis and atrophic vaginitis.
Spectrum of antifungal activity of Miconazole nitrate includes many fungi, including yeasts and dermatophytes. It is particularly active against Candida spp. (C. guilliermondii and C. tropicalis.), Trichophyton spp. (Trichophyton mentagrophytes, and Trichophyton rubrum), Epidermophyton spp. (E. floccosum), Microsporum spp. (M. canis), Pityrosporon orbiculare (Malassezia furfur) and other, but also possesses some activity against Gram-positive bacteria (Staphylococcus aureus).
Spectrum of antifungal activity of Luliconazole includes dermatophytes, yeasts, and some other fungi. It is particularly active against Trichophyton spp. (T. rubrum, T. mentagrophytes and T. tonsurans, T. verrucosum, T. violaceum, Microsporum canis, and M. gypseum, Epidermophyton floccosum), Candida albicans, Malassezia furfur, Malassezia restricta, Malassezia slooffiae, and Malassezia sympodialis and other.
Miconazole and Luliconazole of present invention act as an antifungal which inhibit/prevent vaginal fungal infections.
Miconazole acts by inhibiting the 14a-demethylation of lanosterol, which consequently leads to the inhibition of ergosterol synthesis in fungal cell membranes. Additionally, Miconazole has been shown to induce reactive oxygen species in fungal biofdms, demonstrating a MIC value of >256pM against Candida spp.
Luliconazole acts by inhibiting the ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol.
The vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts; wherein Miconazole or its salts and Luliconazole or its salts is providing potent antifungal activity, efficacy and patient compliance in the treatment of vaginal fungal infection.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention broaden the spectrum of activity, enhance the rate or extent of antifungal or antibacterial activity and reduce toxicities for the treatment of vaginal fungal infection.
In one embodiment, the present invention provides a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
In one embodiment, the present invention discloses a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts.
In one embodiment, the present invention discloses a vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention is formulated into a dosage form selected from a group comprising of pessary, vaginal ring, douche, suppository, tablet, soft capsule, tampon, foam, spray, gel, cream, Intrauterine device (IUD), ointment, paste, lotion, solution, tincture, powder, mousses, cleansers and mucoadhesive vaginal film or like thereof.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts may contain one or more pharmaceutically acceptable excipient selected from the group consisting of bases, emollients, lubricant, thickening agent or thickeners, surfactants, solubilizing or emulsifying agent or emulsifier, co-emulsifier, preservative, antioxidant, humectant, absorbent, permeation enhancer, opacifying agent, chelating agent, gelling agent, acidifying or alkalizing or buffering agent, perfumes or fragrances, antifoaming agent, adherent agent, bioadhesive polymer, vehicle and any other excipient known to the art for making pharmaceutical composition.
The example of bases according to the present invention include but not limited to group comprising of carnauba wax, cetyl alcohol, cetyl ester wax, emulsifying wax, hydrous lanolin, lanolin, lanolin alcohols, vegetable oils and animal fat; coconut oil, bees wax, olive oil, spermaceti wax, sesame oil, almond oil, alcohols, acids and esters; oleic acid, oleyl alcohol, palmitic acid, lauryl alcohol, lauraic acid, myristyl alcohol, ethyl oleate, isopropyl myristicate, ethylene glycol, hydrogenated and sulphated oils; hydrogenated castor, cotton
seed, hydrogenated sulphated castor oils, microcrystalline wax, liquid paraffin, petrolatum, polyethylene glycol, stearic acid, stearyl alcohol, white wax, yellow wax or combination thereof.
The examples of emollients according to the present invention include but not limited to group comprising of waxes, fats, caprylic/capric triglyerides, castor oil, ceteareth-20, ceteareth-30, cetearyl alcohol, ceteth 20, cetostearyl alcohol, cetyl alcohol, cetyl stearyl alcohol, cocoa butter, di-isopropyladipate, glycerin, glyceryl monooleate, glyceryl monostearate, glyceryl stearate, isopropyl myristate, isopropyl palmitate, lanolin, lanolin alcohol, hydrogenated lanolin, liquid paraffins, linoleic acid, mineral oil, oleic acid, white petrolatum, polyethylene glycol, polyoxyethylene glycol fatty alcohol ethers, poly oxypropylene 15 -stearyl ether, propylene glycol stearate, squalane, steareth-2 or -100, stearic acid and urea, oils of natural origin such as almond oil, coconut oil, olive oil, palm oil, peanut oil and the like, fatty acids such as lauric acid, myristic acid, palmitic acid, and stearic acid, monohydric alcohol esters of the fatty acids such as ethyl laurate, isopropyl laurate, ethyl myristate, n-propyl myristate, ethyl palmitate, methyl palmitate, methyl stearate, ethyl stearate, isopropyl stearate, butyl stearate, isobutyl stearate, amyl stearate, and isoamyl stearate, glycols such as ethylene glycol, diethylene glycol, polyethylene glycol, branched aliphatic alcohols such as lauryl alcohol, myristyl alcohol, and stearyl alcohol or combination thereof.
The examples of lubricant according to the present invention include but not limited to group comprising of castor oil, mineral oil, paraffin oil, ispagol mucilage, vitamin D, talc or any mixture thereof. The amount of lubricant present in the composition may ranges from about 0.1-15%; preferably about 0.5-12%; more preferably about 1-10% by weight of composition.
The examples of thickening agent or thickeners according to the present invention include but not limited to group comprising of carbomer, hydrogenated castor oil, methyl cellulose, sodium carboxyl methyl cellulose, carrageenan, colloidal silicon dioxide, natural gum such as gelatin, tragacanth gum and guar gum, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxide, alginic acid, paraffin, cetostearyl alcohol, PEG 200, PEG 300, PEG 400, PEG 600, monoethanolamine, triethanolamine, glycerol, propylene glycol, polyoxyethylene sorbiton monoleate, and poloxamers, polyvinyl pyrrolidone, various
alcohols such as polyvinyl alcohol, ethanol or isopropyl alcohol, fumed silica or combination thereof.
The examples of surfactant according to the present invention include but not limited to group comprising of ionic, cationic and non-ionic surfactants or the like or any mixture thereof, further one or more of surfactant selected from but not limited to polysorbate, polysorbate 20, polysorbate 40, polysorbates 80, polysorbate 60, poloxamer, sorbitan monostearate, sorbitan monooleate, sodium lauryl sulfate, propylene glycol monostearate, dodecyl benzene sulfonate, polyethylene glycol, PEG 100 stearate polyethylene glycol 6000 distearate, polyethylene glycol 1000 monocetyl ether, polyethylene glycol monostearate, polyethylene glycol 400 monostearate, polyoxyethylene glycol fatty alcohol ethers, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, PPG-26 oleate, sorbitan esters, sorbitan monolaurate, sorbitan monopalmitate, sorbitan palmitate, sorbitan sesquioleate, or the like or combination thereof. the examples of solubilizing or emulsifying agent or emulsifier according to the present invention include but not limited to group comprising of apricot kernel oil PEG-6 ester, pegoxol-7 stearate, polysorbate 20, polysorbate 80, polysorbate 60, poloxamer, emulsifying wax, sorbitan monostearate, sorbitan monooleate, sodium lauryl sulfate, propylene glycol monostearate, natural gums like acacia and tragacanth, monovalent and bivalent soaps, lanolin, cholesterol or cholesterol esters, triethanolamine and its salts, dodecyl benzene sulfonate, diethylene glycol monoethyl ether, docusate sodium or mixture thereof, the amount of solubilizing or emulsifying agent or emulsifier present in the composition ranges from about 0.1-25%; preferably 1 to 22% by weight of composition.
The examples of co-emulsifier according to the present invention include but not limited to group comprising of apricot kernel oil PEG-6 ester, propylene glycol stearate, cetyl hydroxyethyl cellulose, poloxamer 407, polyglyceryl-2 stearate or combination thereof, the amount of co-emulsifier present in the composition ranges from about 0.1-10%; preferably 0.05 to 8% by weight of composition.
The example of preservative according to the present invention include but not limited to group comprising of chorocresol, benzoic acid, butylated hydroxyanisole, phenyl mercuric nitrate, benzyl alcohol, benzoic acid and its salts, boric acid, methyl paraben, propyl paraben,
trihydrate and anhydrous sodium acetate, chlorhexidine, formaldehyde, glutaraldehyde, imidazolidinyl urea, trichlosan, benzalkonium chloride, chloroxylenol or combination thereof, the amount of preservative present in the composition may ranges from about 0.001- 6%; preferably about 0.001-5%; more preferably about 0.005-4.5% by weight of composition.
The example of antioxidant according to the present invention include but not limited to group comprising of butylated hydroxylanisole, butylated hydroxyl toluene, propyl gallate, polyols like sorbitol, xylitol and maltitol, natural extracts like quillaia, or lactic acid or urea, lithium chloride, ascorbic acid, sodium metabisulfite, carotinoids, carotenes such as a- carotone, P-carotene and lycopene, chlorogenic acid, tocopherols, uric acid, zno, znso4 or combination thereof.
The example of humectant according to the present invention include but not limited to group comprising of glycerin, glyceryl triacetate, propylene glycol, polyethylene glycol, sorbitol solution, 1,2,6 hexanetriol, isopropyl myristate, petrolatum, isopropyl palmitate, hydrogenated castor oil, mineral oil, polyoxymethylene urea, potassium sorbate or combination thereof.
The example of absorbent according to the present invention include but not limited to group comprising of magnesium carbonate, calcium carbonate, starch, cellulose and its derivatives or combination thereof.
The example of permeation enhancer according to the present invention include but not limited to group comprising of propylene glycol, ethanol, isopropyl alcohol, oleic acid, polyethylene glycol, phospholipids, cyclodextrins, black pepper (piper nigrum), pyrrolidones, dimethyl sulphoxide (dmso), decylmethyl sulphoxide (dems), terpenes (cineole, eugenol, d- limonene, menthol, menthone), urea or combination thereof.
The examples of opacifying agent according to the present invention include but not limited to group comprising of higher fatty alcohols such as cetyl, stearyl, cetostearyl alcohol, arachidyl and behenyl alcohols, solid esters such as cetyl palmitate, glyceryl laurate, various fatty acid derivatives such as propylene glycol and polyethylene glycol esters, inorganic
materials such as, magnesium aluminum silicate, zinc oxide, titanium dioxide or other sunblocking agents or combination thereof.
The example of chelating agent according to the present invention include but not limited to group comprising of ethylene diamine tetraacetate, dimercaprol, dimercaptosuccinic acid, penicillamine, deferoxamine, deferasirox, citric acid, maleic acid, phosphoric acid or combination thereof.
The example of gelling agent according to the present invention include but not limited to group comprising of carbomer/carbopols, pemulen®, cellulose derivatives such as methyl cellulose, hydroxy ethylcellulose, hydroxy propylmethylcellulose, carboxy methyl cellulose, hydroxy propyl cellulose, etc., glycerol, or propylene glycol gelled with suitable agents such as natural gums such as xanthan gum and tragacanth, fenugreek mucilage, pectin, poloxamers (pluronics), alginate, gelatin, starch, polyvinyl alcohol, povidone or combination thereof.
The example of acidifying or alkalizing or buffering agent according to the present invention include but not limited to group comprising of anhydrous and monohydrate citric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium sorbate, monobasic and dibasic sodium phosphate, trolamine or combination thereof.
The example of perfume or fragrances according to the present invention include but not limited to group comprising of lavender, lemon, gardenia, hypo allergenic perfume, menthol or combination thereof.
The example of antifoaming agent according to the present invention include but not limited to group comprising of cyclomethicone, dimethicone and simethicone or combination thereof.
The example of adherent agent according to the present invention include but not limited to group comprising of natural gum (arabic, align, guar, tragacanth and xanthan gums, pectin and dextran) or combination thereof.
The example of bioadhesive polymer according to the present invention include but not limited to group comprising of ethyl cellulose, polyvinylpyrrolidone, hydroxyl propyl methyl
cellulose, hydroxyl propyl cellulose, hydroxyl ethyl cellulose, ethyl cellulose or combination thereof.
The example of vehicle according to the present invention include but not limited to group comprising of purified water, hexylene glycol, propylene glycol, oleyl alcohol, propylene carbonate, mineral oil, almond oil, cottonseed oil, ethyl oleate, isopropyl myristate, isopropyl palmitate, myristyl alcohol, octyldodecanol, olive oil, peanut oil, safflower oil, sesame oil, soybean oil, squalene, polyethylene glycol, diethylene glycol monoethyl, glycofurol, benzyl alcohol, labrasol, benzyl benzoate and ethyl oleate, diethylene glycol monoethyl ether, ethyl alcohol, cremophore ELP, solutol, transcutol, capmul, captex or mixture thereof. Preferably the vehicle is water. The vehicle according to present invention may be present in an amount to make up volume to quantity sufficient.
In one embodiment, the present invention provides a vaginal pharmaceutical composition for treating vaginal infections, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
In one embodiment, the present invention provides a vaginal pharmaceutical composition, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) q.s of vehicle
In one embodiment, the present invention provides a process of preparation of a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts, comprising:
(a) Aqueous phase: dissolving preservative in purified water, mixing and heating at suitable temperature;
(b) Lipid phase: Mixing co-emulsifier, emulsifier, lubricant, and preservative and heating at suitable temperature;
(c) Cooling the lipid phase of step (b) at suitable temperature and mixing both active pharmaceutical ingredients (APIs) for 5-10 minutes;
(d) Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes; and
(e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salt and Luliconazole or salts, wherein said vaginal pharmaceutical composition can be applied at least once a day or as per instructions of healthcare provider.
The vaginal pharmaceutical composition according to present invention can be applied to affected part through hand or suitable applicator.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or salts comprises other pharmaceutically acceptable polymers mainly used for to maintain proper viscosity of formulation.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be manufactured by trituration method, levigation method, fusion method, chemical reaction method, emulsification method, cold method, dispersion method, moulding, compression, hand rolling and shaping, pour moulding, wet granulation, dry granulation or direct compression.
The concentration of active ingredient Miconazole or its salts and Luliconazole or its salts and other excipients, manufacturing process has been optimized in way such that composition will have maximum therapeutic efficacy in the treatment of vaginal fungal infection with minimum or no side effects and which results in better patient compliance.
The synergism of Miconazole or its salts and Luliconazole or its salts according to present invention broaden the spectrum of activity, enhance the rate or extent of antifungal or antibacterial activity, and reduce toxicities in the treatment of vaginal fungal infection.
The vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts is evaluated by determination of pH, primary skin irritation test, visual appearance, viscosity, spreadability, stability studies, rheological studies, thermal behavior, saponification value and acid value.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be loaded for stability studies as per ICH guidelines.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be packaged in to the collapsible tubes, jars, pot, bottle or single dose packets. The container material or packaging material of the present invention does not affect the quality of the preparation or does not allow diffusion of any kind into or across the material of the container into the preparation.
The vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts according to present invention may be labeled according to the requirement under Good Manufacturing Practice.
The following examples serve to illustrate the embodiments of the present invention. However, they do not intend to limit the scope of the invention.
Manufacturing Process:
1. Aqueous phase: Benzoic Acid was dissolved in purified water, mixed and heated at 65- 75°C; 2. Lipid phase: Apricot kernel oil PEG-6 Ester, Pegoxol-7 Stearate, Mineral oil, Butylated hydroxyanisole mixed and heated at 65-75°C;
3. Step 2 phase was allowed to cool at 65 °C and both active pharmaceutical ingredients (APIs) Miconazole nitrate and Luliconazole were mixed for 5-10 minutes;
4. Emulsification was achieved by addition of step 3 to step 1, mixed for 10 minutes, and 5. Manufactured cream was mixed slowly and allowed to cool down at Room temperature.
Example 2: Cream base approach with change in emulsifier and preservative:
q.s.: Quantity sufficient
Manufacturing process:
1. Aqueous phase: Benzoic Acid was dissolved in purified water, mixed and heated at 65- 75°C;
2. Lipid phase: Apricot kernel oil PEG-6 Ester, Pegoxol-7 Stearate, Mineral oil, mixed and heated at 65-75°C;
3. Step 2 phase was allowed to cool at 65 °C and both active pharmaceutical ingredients (APIs) Miconazole nitrate and Luliconazole were mixed for 5-10 minutes;
4. Emulsification was achieved by addition of step 3 to step 1, mixed for 10 minutes, and
5. Manufactured cream was mixed slowly and allowed to cool down at Room temperature.
Claims
1. A vaginal pharmaceutical composition for treating vaginal infections comprising Miconazole or its salts and Luliconazole or its salts with one or more pharmaceutically acceptable excipient.
2. The vaginal pharmaceutical composition for treating vaginal infections as claimed in claim 1, wherein the vaginal pharmaceutical composition comprises: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and vii) quantity sufficient (q.s) of vehicle.
3. The vaginal pharmaceutical composition for treating vaginal infections as claimed in claim 1, wherein the vaginal infection is selected from a group comprising of yeast infections, bacterial vaginosis, trichomoniasis, a sexually transmitted infection (STIs), chlamydia or gonorrhea, viral vaginitis (herpes), trichomoniasis, non-infectious vaginitis, atrophic vaginitis and the like.
4. A vaginal pharmaceutical composition comprising: i) Miconazole or its salts; ii) Luliconazole or its salts; and iii) one or more pharmaceutically acceptable excipients.
5. A vaginal pharmaceutical composition as claimed in claim 4, comprising: i) 0.1 %- 10 % w/w of Miconazole or its salts; ii) 0.01-5 % w/w of Luliconazole or its salts; iii) 0.1-15 % w/w of lubricant; iv) 0.1-25 % w/w of emulsifier; v) 0.1-10 % w/w of co-emulsifier; vi) 0.001-6% w/w of preservative; and
vii) quantity sufficient (q.s) of vehicle.
6. The vaginal pharmaceutical composition as claimed in any one of claim 1 and 4, wherein one or more pharmaceutically acceptable excipient is selected from a group comprising of bases, emollients, lubricant, thickening agent or thickeners, surfactants, solubilizing or emulsifying agent or emulsifier, co-emulsifier, preservative, antioxidant, humectant, absorbent, permeation enhancer, opacifying agent, chelating agent, gelling agent, acidifying or alkalizing or buffering agent, perfumes or fragrances, antifoaming agent, adherent agent, bioadhesive polymer and vehicle and the like or combination thereof.
7. The vaginal pharmaceutical composition as claimed in claim 1 and 4, wherein the composition is formulated into a dosage form selected from a group comprising of pessary, vaginal ring, douche, suppository, tablet, soft capsule, tampon, foam, spray, gel, cream, Intrauterine device (IUD), ointment, paste, lotion, powder, solution, tincture, mousses, cleansers and mucoadhesive vaginal film.
8. A process for preparation of a vaginal pharmaceutical composition comprising Miconazole or its salts and Luliconazole or its salts, comprising:
(a) Aqueous phase: dissolving preservative in purified water, mixing and heating at suitable temperature;
(b) Lipid phase: Mixing co-emulsifier, emulsifier, lubricant and preservative and heating at suitable temperature;
(c) Cooling the lipid phase of step (b) at suitable temperature and mixing both active pharmaceutical ingredients (APIs) for 5-10 minutes;
(d) Emulsification is achieved by adding step (c) to step (a), mixing for 10 minutes; and
(e) cream obtained in step (d) is mixed slowly and allow to cool down at room temperature.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202121037239 | 2022-02-17 | ||
IN202121037239 | 2022-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023157024A1 true WO2023157024A1 (en) | 2023-08-24 |
Family
ID=87579173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2023/050160 WO2023157024A1 (en) | 2022-02-17 | 2023-02-17 | Vaginal pharmaceutical composition comprising miconazole and luliconazole or salts thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023157024A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019003098A1 (en) * | 2017-06-29 | 2019-01-03 | Zenvision Pharma Llp | Topical pharmaceutical composition comprising miconazole and luliconazole or salts thereof |
-
2023
- 2023-02-17 WO PCT/IN2023/050160 patent/WO2023157024A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019003098A1 (en) * | 2017-06-29 | 2019-01-03 | Zenvision Pharma Llp | Topical pharmaceutical composition comprising miconazole and luliconazole or salts thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7285517B2 (en) | Warming and nonirritating lubricant compositions and method of comparing irritation | |
JP2999820B2 (en) | Improved intravaginal treatment of vaginal infections with buffered metronidazole compositions | |
US20070287714A1 (en) | Warming and Nonirritating Lubricant Compositions and Method of Comparing Irritation | |
US20110059985A1 (en) | Novel formulation | |
CA2635992A1 (en) | Medicament for topical use | |
JP2004529935A (en) | Composition comprising an antifungal agent for treating vulvar vaginitis and vaginosis | |
US20090170876A1 (en) | Novel Topical Formulations of Flucytosine | |
US20060165803A1 (en) | Pharmaceutical compositions of sertaconazole for vaginal use | |
US20090068287A1 (en) | Novel topical formulations of flucytosine and uses thereof | |
WO2011121604A2 (en) | A liquid vaginal spray formulation for treatment of vaginal fungal infection | |
WO2014026707A1 (en) | Anti-vaginitis compositions with improved release and adherence | |
ES2532863T3 (en) | Use of nifuratel to treat infections caused by Atopobium species | |
US20030130225A1 (en) | Novel methods of treating local fungal and bacterial infections | |
EP1764100A2 (en) | Compositions and methods for reducing vaginal pH | |
US11266600B2 (en) | Emulsions for the topical treatment of dermal and mucosal infections | |
US20040185065A1 (en) | Warming and nonirritating lubricant compositions and method of comparing irritation | |
WO2023157024A1 (en) | Vaginal pharmaceutical composition comprising miconazole and luliconazole or salts thereof | |
US20060172007A1 (en) | Compositions and methods for reducing vaginal pH | |
WO2019003098A1 (en) | Topical pharmaceutical composition comprising miconazole and luliconazole or salts thereof | |
US20230310460A1 (en) | Low Dose Topical Composition Comprising Triamcinolone Acetonide or Salt Thereof | |
RU2479305C2 (en) | Pharmaceutical composition for treating infectious inflammatory diseases and method for preparing it | |
RU2498806C2 (en) | Pharmaceutical formulation for treating infectious inflammatory gynaecological disorders and method for preparing it | |
JPH0234924B2 (en) | IMIDAZOORUJUDOTAIOFUKUMUHININNYUYONASOSEIBUTSU | |
Sharp et al. | Topical Azoles | |
TR2021019832A2 (en) | A topical pharmaceutical composition containing fenticonazole nitrate. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23756024 Country of ref document: EP Kind code of ref document: A1 |